- Home
- CRIS vs PFSA Comparison
CRIS vs PFSA Comparison
Compare CRIS & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- PFSA
- Stock Information
- Founded
- CRIS 2000
- PFSA 2009
- Country
- CRIS United States
- PFSA United States
- Employees
- CRIS N/A
- PFSA N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- PFSA Medical/Dental Instruments
- Sector
- CRIS Health Care
- PFSA Health Care
- Exchange
- CRIS Nasdaq
- PFSA Nasdaq
- Market Cap
- CRIS 22.9M
- PFSA 25.1M
- IPO Year
- CRIS 2000
- PFSA N/A
- Fundamental
- Price
- CRIS $1.71
- PFSA $0.50
- Analyst Decision
- CRIS Strong Buy
- PFSA
- Analyst Count
- CRIS 2
- PFSA 0
- Target Price
- CRIS $16.50
- PFSA N/A
- AVG Volume (30 Days)
- CRIS 70.9K
- PFSA 7.5M
- Earning Date
- CRIS 08-05-2025
- PFSA 01-01-0001
- Dividend Yield
- CRIS N/A
- PFSA N/A
- EPS Growth
- CRIS N/A
- PFSA N/A
- EPS
- CRIS N/A
- PFSA N/A
- Revenue
- CRIS $11,405,000.00
- PFSA $75,000.00
- Revenue This Year
- CRIS N/A
- PFSA N/A
- Revenue Next Year
- CRIS $9.52
- PFSA N/A
- P/E Ratio
- CRIS N/A
- PFSA N/A
- Revenue Growth
- CRIS 12.24
- PFSA 150.00
- 52 Week Low
- CRIS $1.02
- PFSA $0.46
- 52 Week High
- CRIS $8.29
- PFSA $5.50
- Technical
- Relative Strength Index (RSI)
- CRIS 48.40
- PFSA N/A
- Support Level
- CRIS $1.47
- PFSA N/A
- Resistance Level
- CRIS $1.79
- PFSA N/A
- Average True Range (ATR)
- CRIS 0.14
- PFSA 0.00
- MACD
- CRIS 0.01
- PFSA 0.00
- Stochastic Oscillator
- CRIS 57.32
- PFSA 0.00
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About PFSA Profusa Inc. Common Stock
Profusa Inc is a digital health technology company based in Emeryville, CA, that has developed a real-time, consumer-friendly platform that is designed to measure an individual's biochemistry, be easy to use, be cost-effective, and provide the necessary data to manage chronic disease and health and wellness decisions to improve health outcomes for a large population of potential users. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.